Pharmaceuticals

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

A new compound could make CAR-T cell therapy more durable and less costly, showing promise against both cancer and HIV in groundbreaking new research.

With its lead autoimmune drug nearing FDA review and a new $250M in funding, Zenas BioPharma prepares for a major leap from R&D to market.

Inc. names Tiffany Whitlow to its Female Founders 500, validating Acclinate's model of making inclusive clinical research a profitable, high-growth venture.

Nasus Pharma's NS002 nasal spray reached critical therapeutic levels in half the time of EpiPen, heralding a potential new era for anaphylaxis treatment.

As MediciNova execs meet investors at the ROTH Conference, all eyes are on pivotal updates for its ALS, MS, and NAFLD drug candidates.

New data on an oral Parkinson's drug and major strides in rare disease research signal Lundbeck's deep commitment to tackling complex neurological disorders.

Actelion Pharmaceuticals settles a class action lawsuit for $65M, accused of illegally blocking a cheaper generic for its life-saving hypertension drug.

OTC-listed ProText Mobility unveils an audacious plan to tokenize biotech assets, partner with major banks, and uplist to a major exchange. Can it deliver?

As AI chips push power and heat limits, Compal debuts its "ONE Integrated Solution" at GTC 2026, a unified rack system aimed at defining the future of data centers.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Western Alliance Bank launches a specialized healthcare banking division led by Jennifer Hwang, aiming to serve a complex and rapidly evolving industry.

As employers grapple with soaring obesity drug costs, a new partnership aims to offer predictable pricing and comprehensive care. Here's how it works.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

A landmark review decodes how ketogenic diets treat epilepsy, highlighting a major research gap and sparking a quest for drugs that mimic the diet's effects.

Medical Knowledge Group appoints Waymo's David Margines, signaling a major shift in how high-stakes AI will reshape pharmaceutical marketing and strategy.

Global CRO Emerald Clinical Trials has won a major award for its patient-first strategies in the fast-growing, complex Asia-Pacific clinical trial market.

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.